Rosenberg Matthew Hamilton lessened its stake in AbbVie Inc. (NYSE:ABBV – Free Report) by 2.2% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,131 shares of the company’s stock after selling 92 shares during the period. Rosenberg Matthew Hamilton’s holdings in AbbVie were worth $658,000 as of its most recent SEC filing.
Several other institutional investors have also recently added to or reduced their stakes in ABBV. Oliver Lagore Vanvalin Investment Group increased its position in AbbVie by 85.3% in the 3rd quarter. Oliver Lagore Vanvalin Investment Group now owns 202 shares of the company’s stock valued at $27,000 after acquiring an additional 93 shares during the period. Align Wealth Management LLC acquired a new position in AbbVie during the 4th quarter worth approximately $27,000. Red Tortoise LLC acquired a new position in AbbVie during the 4th quarter worth approximately $27,000. Boulder Wealth Advisors LLC acquired a new position in AbbVie during the 4th quarter worth approximately $31,000. Finally, My Personal CFO LLC acquired a new position in AbbVie during the 4th quarter worth approximately $32,000. Institutional investors and hedge funds own 68.27% of the company’s stock.
Insider Buying and Selling at AbbVie
In other AbbVie news, EVP Perry C. Siatis sold 3,520 shares of the business’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $160.00, for a total value of $563,200.00. Following the completion of the transaction, the executive vice president now directly owns 10,377 shares in the company, valued at approximately $1,660,320. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, EVP Perry C. Siatis sold 3,520 shares of the company’s stock in a transaction on Monday, April 3rd. The stock was sold at an average price of $160.00, for a total transaction of $563,200.00. Following the completion of the sale, the executive vice president now directly owns 10,377 shares in the company, valued at approximately $1,660,320. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Elaine K. Sorg sold 7,499 shares of the company’s stock in a transaction on Monday, April 17th. The stock was sold at an average price of $161.67, for a total value of $1,212,363.33. Following the sale, the senior vice president now owns 35,330 shares of the company’s stock, valued at $5,711,801.10. The disclosure for this sale can be found here. In the last three months, insiders sold 32,151 shares of company stock worth $5,187,783. Insiders own 0.26% of the company’s stock.
Analysts Set New Price Targets
AbbVie Price Performance
ABBV stock opened at $132.51 on Thursday. AbbVie Inc. has a 1 year low of $130.96 and a 1 year high of $168.11. The company has a debt-to-equity ratio of 4.46, a quick ratio of 0.82 and a current ratio of 0.96. The stock’s 50 day moving average price is $143.33 and its 200 day moving average price is $151.39. The firm has a market cap of $233.79 billion, a P/E ratio of 31.33, a PEG ratio of 2.46 and a beta of 0.58.
AbbVie (NYSE:ABBV – Free Report) last issued its quarterly earnings results on Thursday, April 27th. The company reported $2.46 earnings per share for the quarter, beating the consensus estimate of $2.44 by $0.02. The company had revenue of $12.23 billion during the quarter, compared to the consensus estimate of $12.23 billion. AbbVie had a return on equity of 153.92% and a net margin of 13.37%. AbbVie’s revenue was down 9.7% on a year-over-year basis. During the same period in the previous year, the firm posted $3.16 EPS. On average, sell-side analysts expect that AbbVie Inc. will post 10.97 earnings per share for the current fiscal year.
AbbVie Announces Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, August 15th. Shareholders of record on Friday, July 14th will be issued a $1.48 dividend. The ex-dividend date of this dividend is Thursday, July 13th. This represents a $5.92 annualized dividend and a yield of 4.47%. AbbVie’s dividend payout ratio (DPR) is presently 139.95%.
About AbbVie
AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, a therapy administered as an injection for autoimmune, intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq, a JAK inhibitor to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, and ulcerative colitis; Imbruvica for the treatment of adult patients with blood cancers; and Venclexta/Venclyxto to treat hematological malignancies.
Featured Articles
- Five stocks we like better than AbbVie
- AMD’s Recent Correction: A Buying Opportunity For Investors?
- AeroVironment’s New Momentum Makes it a Value Play
- Unifirst: Undervalued At Rock-Bottom Prices
- Jefferies Misses on Earnings: Does it Signal a Speed Bump or U-Turn?
- General Mills Retreats To The Buy Zone
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
